The minimal clinically important difference, or MCID, has become a central tool for judging whether spine surgery actually helped a patient. But treating it as a fixed, one-size-fits-all number can create a false sense of precision, according to an article in the summer 2026 issue of Vertebral Columns.
MCID refers to the smallest change in an outcome score that patients perceive as meaningful, or that justifies a change in management. In spine surgery, it is typically applied to patient-reported outcome measures such as the Oswestry Disability Index, Neck Disability Index, visual analog and numeric pain scales, SRS-22, EQ-5D and PROMIS. It shifts the question from whether a change is statistically detectable to whether it is relevant to the person living with the result.
- The number is not built into the questionnaire. MCID is an estimate produced by a method, and the methods disagree. Anchor-based, distribution-based and receiver-operating-characteristic approaches can generate different thresholds for the same measure in the same population. The authors cited work by Copay and colleagues showing that different calculation methods produced different MCID estimates for the ODI, SF-36 and pain scales, underscoring that MCID is method-dependent, rather than a fixed value.
- Thresholds are not interchangeable across measures. A clinically meaningful improvement in pain does not necessarily correspond to a meaningful improvement in disability or quality of life. The authors pointed to colleagues, who found MCID estimates varied widely across PROMIS, NDI and ODI instruments among patients with spinal conditions.
- Baseline severity, diagnosis and timing all move the target. A patient with severe preoperative disability has more room to improve than one with mild symptoms. Authors found that a 30% reduction from baseline in pain and disability performed as well as or better than fixed absolute thresholds after lumbar spine surgery, especially at the extremes of baseline severity. Follow-up timing matters too: in one lumbar cohort, three-month ODI outcomes did not fully capture 12-month improvement, suggesting early assessment can understate meaningful recovery.
Reaching MCID also does not mean a patient is satisfied or has reached an acceptable health state, the authors said. MCID measures change from baseline, not final symptom burden. Related metrics answer different questions: patient acceptable symptom state, or PASS, reflects whether a patient considers their current state acceptable, while substantial clinical benefit, or SCB, reflects a larger magnitude of improvement.
Rather than abandoning MCID, the authors argued it should be interpreted more flexibly and in clinical context. They suggested pairing it with percentage-improvement thresholds, PASS, SCB and patient-specific goals for a fuller picture of recovery.
The article concluded that MCID remains valuable because it translates PROM changes into clinically meaningful information, but “should not be used as a one-size-fits-all measure.” Relying on a single fixed threshold, the authors wrote, may oversimplify a recovery process that is inherently variable across patients, and MCID “should guide outcome interpretation, but it should not replace clinical judgment or patient-centered assessment.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
